Buell Jennifer

SEC source: 0001193125-26-421529 · ownership.xml · nonDerivative · entry 2

Buell Jennifer · CIK 0001711184 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,195

F2 · shares: Represents sales of shares, as a consequence of the vesting of restricted stock units, solely to satisfy tax withholding obligations incurred upon vesting.

F3 · price: Represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.33 to $10.61. The reporting person undertakes to provide to the Company, any shareholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001193125-26-421529 · ownership.xml · derivative · entry 3

Buell Jennifer · CIK 0001711184 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,382

Underlying: Common Stock · 23,191 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MiNK Therapeutics, Inc. (the "Company").

F4 · derivative.exercise_date: On October 11, 2023 the reporting person was granted RSUs under the Company's 2021 Equity Incentive Plan, vesting in three substantially equal annual installments on each of the third, fourth and fifth anniversaries of the grant date. This award was previously reported as covering 695,750 RSUs but was adjusted to 69,573 RSUs to reflect the 1-for-10 reverse stock split (rounding) that occurred on January 28, 2025.

F4 · derivative.expiration_date: On October 11, 2023 the reporting person was granted RSUs under the Company's 2021 Equity Incentive Plan, vesting in three substantially equal annual installments on each of the third, fourth and fifth anniversaries of the grant date. This award was previously reported as covering 695,750 RSUs but was adjusted to 69,573 RSUs to reflect the 1-for-10 reverse stock split (rounding) that occurred on January 28, 2025.

SEC source: 0001193125-26-421529 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,133

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MiNK Therapeutics, Inc. (the "Company").

SEC source: 0001193125-26-339949 · ownership.xml · derivative · entry 1

Buell Jennifer · CIK 0001711184 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2036-08-05

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vest over three (3) years, with one-third (1/3) vesting on the first anniversary of the Grant Date and the remaining two-thirds (2/3) vesting in two equal annual installments thereafter.

SEC source: 0001193125-26-187085 · ownership.xml · derivative · entry 2

Buell Jennifer · CIK 0001711184 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2036-04-24

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on April 24, 2027 and the balance vesting in equal quarterly installments thereafter.

SEC source: 0001193125-26-187085 · ownership.xml · derivative · entry 1

Buell Jennifer · CIK 0001711184 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2036-04-24

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on April 24, 2027 and the balance vesting in equal quarterly installments thereafter.

SEC source: 0001193125-26-004799 · ownership.xml · derivative · entry 2

Buell Jennifer · CIK 0001711184 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2036-01-02

F3 · derivative.exercise_date: The option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the date of grant, with the remainder vesting in eight equal quarterly installments thereafter.

SEC source: 0001193125-26-004799 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,966

F1 · security: Reflects the executive's 2025 performance bonus award paid in MiNK Therapeutics, Inc. common stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 100% of the award released on February 2, 2026.

F2 · price: $11.12 was the fair market value of MiNK Therapeutics, Inc. Common Stock on January 2, 2026, the stock issuance date.

SEC source: 0001193125-26-012914 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,942

F1 · shares: These shares were withheld for payment of the withholding taxes in relation to the stock issued to the reporting person on January 2, 2026, as previously reported on the Form 4 filed on January 6, 2026 (the "Original Form 4"). The Original Form 4 did not include the shares withheld for payment of withholding taxes in Table I. This amendment is being filed to correct this error.

SEC source: 0001193125-25-201376 · ownership.xml · derivative · entry 2

Buell Jennifer · CIK 0001711184 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2035-09-09

F3 · derivative.exercise_date: The option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the date of grant, with the remainder vesting in eight equal quarterly installments thereafter, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.

SEC source: 0001193125-25-201376 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,913

F1 · security: Reflects the executive's 2024 performance bonus award paid in MiNK Therapeutics, Inc. common stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 100% of the award released on October 9, 2025.

F2 · price: $15.36 was the fair market value of MiNK Therapeutics, Inc. Common Stock on September 9, 2025, the stock issuance date.

SEC source: 0001193125-25-230098 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,492

F1 · shares: These shares were withheld for payment of the withholding taxes in relation to the stock issued to reporting person on September 9, 2025, as previously reported on the Form 4 filed on September 11, 2025 (the "Original Form 4"). The Original Form 4 did not include the shares withheld for payment of withholding taxes in Table I. This amendment is being filed to correct this error.

SEC source: 0000950170-25-064636 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,738

F1 · security: At her request and with the approval of the Agenus Inc. Compensation Committee, a portion of Jennifer Buell's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Buell's salary for the pay period ending May 2, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.11 is the closing price of our Common Stock on May 2, 2025, the payroll date for the pay period ending May 2, 2025.

SEC source: 0000950170-25-063522 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,157

F1 · security: At her request and with the approval of the Agenus Inc. Compensation Committee, a portion of Jennifer Buell's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Buell's salary for the pay period ending April 18, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $2.08 is the closing price of our Common Stock on April 17, 2025, the payroll date for the pay period ending April 18, 2025.

SEC source: 0000950170-25-052895 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,288

F1 · security: At her request and with the approval of the Agenus Inc. Compensation Committee, a portion of Jennifer Buell's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Buell's salary for the pay period ending April 4, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $1.56 is the closing price of our Common Stock on April 4, 2025, the payroll date for the pay period ending April 4, 2025.

SEC source: 0000950170-25-046050 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,129

F1 · security: At her request and with the approval of the Agenus Inc. Compensation Committee, a portion of Jennifer Buell's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Buell's salary for the pay period ending March 21, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $1.61 is the closing price of our Common Stock on March 21, 2025, the payroll date for the pay period ending March 21, 2025.

SEC source: 0000950170-25-043817 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,646

F1 · security: At her request and with the approval of the Agenus Inc. Compensation Committee, a portion of Jennifer Buell's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Buell's salary for the pay period ending March 7, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $2.35 is the closing price of our Common Stock on March 7, 2025, the payroll date for the pay period ending March 7, 2025.

SEC source: 0000950170-25-033526 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,318

F1 · security: At her request and with the approval of the Agenus Inc. Compensation Committee, a portion of Jennifer Buell's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Buell's salary for the pay period ending February 21, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.32 is the closing price of our Common Stock on February 21, 2025, the payroll date for the pay period ending February 21, 2025.

SEC source: 0000950170-25-037127 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,237

F1 · security: At her request and with the approval of the Agenus Inc. Compensation Committee, a portion of Jennifer Buell's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Buell's salary for the pay period ending February 21, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.32 is the closing price of our Common Stock on February 21, 2025, the payroll date for the pay period ending February 21, 2025.

SEC source: 0000950170-25-022204 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,692

F1 · security: At her request and with the approval of the Agenus Inc. Compensation Committee, a portion of Jennifer Buell's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Buell's salary for the pay period ending February 7, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.50 is the closing price of our Common Stock on February 7, 2025, the payroll date for the pay period ending February 7, 2025.

SEC source: 0000950170-25-010023 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,446

F1 · security: At her request and with the approval of the Agenus Inc. Compensation Committee, a portion of Jennifer Buell's salary is being paid in stock, in lieu of cash. The amount reported herein represents the gross amount of Dr. Buell's salary for the pay period ending January 24, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.57 is the closing price of our Common Stock on January 24, 2025, the payroll date for the pay period ending January 24, 2025.

SEC source: 0000950170-25-013409 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,176

F1 · security: At her request and with the approval of the Agenus Inc. Compensation Committee, a portion of Jennifer Buell's salary is being paid in stock, in lieu of cash. The amount reported herein represents payment of tax liability by withholding securities incident to the receipt of securities issued in accordance with Rule 16b-3, for the pay period ending January 24, 2025.

F2 · price: $3.57 is the closing price of our Common Stock on January 24, 2025, the payroll date for the pay period ending January 24, 2025.

SEC source: 0000950170-24-127931 · ownership.xml · derivative · entry 1

Buell Jennifer · CIK 0001711184 · Director · Chairman Executive Council

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2034-11-14

F1 · derivative.exercise_date: Represents a one-time retention award comprised of options to purchase common stock, which were granted to certain key employees, including our executive officers. These options were awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and will vest on November 15, 2025.

SEC source: 0001493152-24-012071 · ownership.xml · derivative · entry 1

Buell Jennifer · CIK 0001711184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: PTIX Common Stock, Par Value $0.0001 · 75,000 shares

Expires 2034-03-25

F1 · derivative.exercise_date: 50,000 of the options are fully-exerciseable on March 25, 2026. The other 25,000 of the options are exercisable on and after the date upon which the company consummates a corporate partnership, if that occurs before December 31, 2026. If the company does not enter into a corporate partnership before December 31, 2026, then those 25,000 options are never exercisable.

SEC source: 0000950170-24-005562 · ownership.xml · derivative · entry 2

Buell Jennifer · CIK 0001711184 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 660,919

Underlying: Common Stock · 660,919 shares

Expires 2034-01-16

F2 · derivative.exercise_date: An option to purchase Common Stock was granted to Dr. Buell on January 16, 2024 for her performance in 2023, and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. Half of the options will vest on June 27, 2024 and half of the options will vest on September 27, 2024

SEC source: 0000950170-24-005562 · ownership.xml · derivative · entry 1

Buell Jennifer · CIK 0001711184 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2034-01-16

F1 · derivative.exercise_date: An option to purchase Common Stock was granted to Dr. Buell on January 16, 2024 and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. The option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter.

SEC source: 0000950170-23-053381 · ownership.xml · derivative · entry 2

Buell Jennifer · CIK 0001711184 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 695,750 shares

Expires not disclosed

F2 · derivative.exercise_price: On October 11, 2023, in alignment with the Company's 2021 Equity Incentive Plan, Dr. Buell received a grant of 695,750 RSUs. This new grant serves as a replacement for the RSUs initially awarded during the Company's IPO, which Dr. Buell forfeited and returned to the Company on October 11, 2023. These newly granted RSUs will vest over a five-year period, with one-third of the restricted stock units vesting on each of the third, fourth and fifth anniversaries of the grant date.

F2 · derivative.exercise_date: On October 11, 2023, in alignment with the Company's 2021 Equity Incentive Plan, Dr. Buell received a grant of 695,750 RSUs. This new grant serves as a replacement for the RSUs initially awarded during the Company's IPO, which Dr. Buell forfeited and returned to the Company on October 11, 2023. These newly granted RSUs will vest over a five-year period, with one-third of the restricted stock units vesting on each of the third, fourth and fifth anniversaries of the grant date.

F2 · derivative.expiration_date: On October 11, 2023, in alignment with the Company's 2021 Equity Incentive Plan, Dr. Buell received a grant of 695,750 RSUs. This new grant serves as a replacement for the RSUs initially awarded during the Company's IPO, which Dr. Buell forfeited and returned to the Company on October 11, 2023. These newly granted RSUs will vest over a five-year period, with one-third of the restricted stock units vesting on each of the third, fourth and fifth anniversaries of the grant date.

SEC source: 0000950170-23-053381 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 232,165

F1 · kind: Dr. Jennifer Buell was awarded Restricted Stock Units ("RSUs") which corresponded to 695,750 shares of MiNK Therapeutics, Inc. ("Company") common stock ("Common Stock"). These RSUs, tied to the Company's Initial Public Offering ("IPO"), vested on September 27, 2023. Dr. Buell previously reported on Form 4s the receipt of such shares of Common Stock (the "RSU Shares") and subsequent sales of shares of Common Stock to cover Federal, state and local tax withholding requirements. However, the Company and Dr. Buell agreed that it is in the best interests of the Company and its stockholders for Dr. Buell to forfeit that award in lieu of a new award that will vest over a period of five years (see Explanation of Responses #2). Therefore Dr. Buell is returning the RSU Shares to the Company. Dr Buell has thus made the Company whole for the forfeited award by returning 695,750 shares of Company Common Stock to the Company on October 11, 2023 for no consideration.

F1 · price: Dr. Jennifer Buell was awarded Restricted Stock Units ("RSUs") which corresponded to 695,750 shares of MiNK Therapeutics, Inc. ("Company") common stock ("Common Stock"). These RSUs, tied to the Company's Initial Public Offering ("IPO"), vested on September 27, 2023. Dr. Buell previously reported on Form 4s the receipt of such shares of Common Stock (the "RSU Shares") and subsequent sales of shares of Common Stock to cover Federal, state and local tax withholding requirements. However, the Company and Dr. Buell agreed that it is in the best interests of the Company and its stockholders for Dr. Buell to forfeit that award in lieu of a new award that will vest over a period of five years (see Explanation of Responses #2). Therefore Dr. Buell is returning the RSU Shares to the Company. Dr Buell has thus made the Company whole for the forfeited award by returning 695,750 shares of Company Common Stock to the Company on October 11, 2023 for no consideration.

SEC source: 0000950170-23-051760 · ownership.xml · nonDerivative · entry 3

Buell Jennifer · CIK 0001711184 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 927,915

F3 · price: Represents sales of shares, as a consequence of the vesting of restricted stock units, to cover Federal, state and local tax withholding requirements. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.875 to $1.02. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-23-051760 · ownership.xml · nonDerivative · entry 2

Buell Jennifer · CIK 0001711184 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 992,915

F2 · price: Represents sales of shares, as a consequence of the vesting of restricted stock units, to cover Federal, state and local tax withholding requirements. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.99 to $1.20. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-23-051760 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,051,465

F1 · price: Represents sales of shares, as a consequence of the vesting of restricted stock units, to cover Federal, state and local tax withholding requirements. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.08 to $1.23. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-23-050807 · ownership.xml · derivative · entry 2

Buell Jennifer · CIK 0001711184 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 695,750

Underlying: Common Stock · 0 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F2 · derivative.exercise_date: Represents restricted stock unit convertible into an equivalent number of shares of our common stock, which vested as to 100% of the underlying shares on September 27, 2023.

F2 · derivative.expiration_date: Represents restricted stock unit convertible into an equivalent number of shares of our common stock, which vested as to 100% of the underlying shares on September 27, 2023.

SEC source: 0000950170-23-050807 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,076,465

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

SEC source: 0000899243-23-001620 · doc4.xml · derivative · entry 2

Buell Jennifer · CIK 0001711184 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2033-01-09

F3 · derivative.exercise_date: Option was granted on January 9, 2023 and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. Option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter.

SEC source: 0000899243-23-001620 · doc4.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 380,715

F1 · security: Reflects the executive's 2022 performance bonus award paid in MiNK Therapeutics, Inc. common stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 50% of the award released on March 24, 2023 and 50% of the award released on June 24, 2023.

F2 · price: $2.32 was the fair market value of MiNK Therapeutics, Inc. Common Stock on January 9, 2023, the stock issuance date.

SEC source: 0000899243-22-003172 · doc4.xml · derivative · entry 1

Buell Jennifer · CIK 0001711184 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 679,800

Underlying: Common Stock · 679,800 shares

Expires 2032-01-21

F1 · derivative.exercise_date: Represents an option to purchase shares of the common stock, which vests as to 35% of the underlying shares on January 21, 2025 and as to the remaining 65% of the underlying shares on January 21, 2026; provided that the Reporting Person maintains a business relationship with the Issuer through each such vesting date.

SEC source: 0000899243-21-027356 · doc4.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · COO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,091

F1 · security: The stock issued is fully-vested on the date of issuance, but is subject to a 12-month lockup restriction.

SEC source: 0000899243-21-027356 · doc4.xml · derivative · entry 2

Buell Jennifer · CIK 0001711184 · COO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 900,000

Underlying: Common Stock · 900,000 shares

Expires 2030-12-17

F2 · derivative.exercise_date: Option was granted on January 1, 2021, subject to shareholder approval of an increase to the available pool under the Company's 2019 Equity Incentive Plan ("2019 Plan"), which was obtained at the Company's annual shareholder meeting on June 15, 2021. Option awarded in accordance with the 2019 Plan. Option vests over a four-year period, with 1/3 of Option vesting on December 17, 2022, and the balance vesting in eight equal quarterly installments thereafter.

SEC source: 0000899243-21-014727 · doc4.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,494

F1 · security: All Agenus employees were given the option to receive their 2020 bonus awards in cash or Agenus stock. Dr. Armen, Dr. Buell and Ms. Klaskin have all chosen to receive their entire 2020 bonus award in Agenus stock rather than cash. The stock issued is fully-vested on the date of issuance, but is subject to a 6-month lockup restriction.

F2 · price: $2.87 is the fair market value of our Common Stock on April 2, 2021, the stock issuance date.

SEC source: 0001745285-20-000042 · primary_doc.xml · derivative · entry 1

Buell Jennifer · CIK 0001711184 · COO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 900,000

Underlying: Common Stock · 900,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Stock Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. One-third of the Stock Option vests on December 17, 2021, with the remaining vesting in eight equal quarterly installments thereafter (provided Dr. Buell maintains a service relationship with the Company through each such vesting date).

SEC source: 0001493152-20-013713 · ownership.xml · derivative · entry 1

Buell Jennifer · CIK 0001711184 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,000

Underlying: PTIX Common Stock, Par Value $0.0001 · 145,000 shares

Expires 2030-07-18

SEC source: 0001745285-20-000010 · primary_doc.xml · derivative · entry 1

Buell Jennifer · CIK 0001711184 · COO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2030-06-15

F1 · derivative.exercise_date: Option was granted on June 15, 2020 in accordance with the Agenus Inc. 2019 Equity Incentive Plan. Option vests in full on June 15, 2021.

SEC source: 0001745285-19-000019 · primary_doc.xml · derivative · entry 1

Buell Jennifer · CIK 0001711184 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2029-12-24

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. Option vests over a three-year period, with 1/3 of Option vesting on December 24, 2020, and the balance vesting in equal quarterly installments thereafter.

SEC source: 0001745285-19-000008 · primary_doc.xml · derivative · entry 1

Buell Jennifer · CIK 0001711184 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,000

Underlying: Common Stock · 84,000 shares

Expires 2029-07-23

F1 · derivative.exercise_date: Stock option awarded in accordance with Agenus Inc. 2019 Equity Incentive Plan and is eligible to vest, if at all, in a single installment on June 30, 2022 based upon the Company stock price performance. Amount shown reflects the target award. The ultimate award size can range between 0% and 150% of target based on the actual average stock price achieved at the end of the performance period.

SEC source: 0000899243-19-017825 · doc4.xml · derivative · entry 1

Buell Jennifer · CIK 0001711184 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2029-01-01

F1 · derivative.exercise_date: Option was granted on January 1, 2019, subject to shareholder approval of the Company's 2019 Equity Incentive Plan, which was obtained at the Company's annual shareholder meeting on June 19, 2019. Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan. Option vests over a three year period, with 1/3 of Option vesting on January 1, 2020, and the balance vesting in equal quarterly installments thereafter.

SEC source: 0000899243-18-028888 · doc4.xml · derivative · entry 1

Buell Jennifer · CIK 0001711184 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 130,000 shares

Expires 2027-11-07

F1 · derivative.exercise_date: Represents the grant of an option to purchase shares of common stock. The stock option was awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Investment Plan, and vests over three years with one-third of the award vesting on November 7, 2019 and the balance vesting in equal quarterly installments thereafter.

SEC source: 0001288123-18-000009 · primary_doc.xml · derivative · entry 1

Buell Jennifer · CIK 0001711184 · Chief Communications Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2028-03-02

F1 · derivative.exercise_date: Option was granted on March 2, 2018 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 20, 2018. Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 equity Inventive Plan, and vests over three years with one-third of the award vesting on March 2, 2019 and the balance vesting in equal quarterly installments thereafter.

SEC source: 0001288123-17-000043 · primary_doc.xml · nonDerivative · entry 2

Buell Jennifer · CIK 0001711184 · Chief Communications Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,656

F2 · kind: Represents sales of shares sold solely to cover Federal, state and local tax withholding requirements on the restricted shares settled and were sold at prices ranging between $3.49 and 3.43 per share.

F2 · price: Represents sales of shares sold solely to cover Federal, state and local tax withholding requirements on the restricted shares settled and were sold at prices ranging between $3.49 and 3.43 per share.

SEC source: 0001288123-17-000043 · primary_doc.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Chief Communications Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,167

F1 · kind: Represents settlement of restricted shares awarded on July 1, 2016.

SEC source: 0001288123-17-000033 · primary_doc.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · VP Research & External Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,736

F1 · kind: Represents the settlement of restricted stock awarded on September 3, 2013.